T1	Pharmacological_substance 19 29	cytarabine
N1000 	Reference T1 MeSH:D003561	cytarabine
T4	Disorder 131 159	acute lymphoblastic leukemia
N1 	Reference T4 UMLS:C0023449	acute lymphoblastic leukemia
T5	Disorder 164 186	lymphoblastic lymphoma
N2 	Reference T5 UMLS:C0079748	lymphoblastic lymphoma
T9	Pharmacological_substance 484 494	cytarabine
N1001 	Reference T9 MeSH:D003561	cytarabine
T10	Pharmacological_substance 496 501	Ara-C
N1002 	Reference T10 MeSH:D003561	Ara-C
T12	Pharmacological_substance 518 530	methotrexate
N1003 	Reference T12 MeSH:D008727	methotrexate
T13	Pharmacological_substance 532 535	MTX
N1004 	Reference T13 MeSH:D008727	MTX
T14	Disorder 622 650	acute lymphoblastic leukemia
N3 	Reference T14 UMLS:C0023449	acute lymphoblastic leukemia
T15	Disorder 652 655	ALL
N4 	Reference T15 UMLS:C0023449	ALL
T16	Disorder 660 699	stage III and IV lymphoblastic lymphoma
N5 	Reference T16 UMLS:C0079748	stage III and IV lymphoblastic lymphoma
T19	Disorder 874 877	ALL
N6 	Reference T19 UMLS:C0023449	ALL
T20	Disorder 881 920	stage III and IV lymphoblastic lymphoma
N7 	Reference T20 UMLS:C0079748	stage III and IV lymphoblastic lymphoma
T22	Pharmacological_substance 967 970	MTX
N1005 	Reference T22 MeSH:D008727	MTX
T25	Pharmacological_substance 1050 1053	MTX
N1006 	Reference T25 MeSH:D008727	MTX
T27	Pharmacological_substance 1115 1120	Ara-C
N1007 	Reference T27 MeSH:D003561	Ara-C
T29	Pharmacological_substance 1190 1193	MTX
N1008 	Reference T29 MeSH:D008727	MTX
T31	Disorder 1270 1273	ALL
N8 	Reference T31 UMLS:C0023449	ALL
T32	Disorder 1292 1314	lymphoblastic lymphoma
N9 	Reference T32 UMLS:C0079748	lymphoblastic lymphoma
T33	Pharmacological_substance 1382 1387	Ara-C
N1009 	Reference T33 MeSH:D003561	Ara-C
T36	Pharmacological_substance 1412 1417	Ara-C
N1010 	Reference T36 MeSH:D003561	Ara-C
T37	Disorder 1463 1469	deaths
N10 	Reference T37 UMLS:C1306577	deaths
T44	Disorder 1924 1927	ALL
N11 	Reference T44 UMLS:C0023449	ALL
T50	Pharmacological_substance 2054 2057	MTX
N1011 	Reference T50 MeSH:D008727	MTX
T51	Pharmacological_substance 2088 2091	MTX
N1012 	Reference T51 MeSH:D008727	MTX
T52	Disorder 2124 2127	ALL
N12 	Reference T52 UMLS:C0023449	ALL
T53	Disorder 2131 2170	stage III and IV lymphoblastic lymphoma
N13 	Reference T53 UMLS:C0079748	stage III and IV lymphoblastic lymphoma
T56	Pharmacological_substance 2325 2330	Ara-C
N1013 	Reference T56 MeSH:D003561	Ara-C
T59	Pharmacological_substance 2343 2346	MTX
N1014 	Reference T59 MeSH:D008727	MTX
T3	Subject 593 601	children
T60	Disorder 564 567;581 589	CNS relapses
N14 	Reference T60 UMLS:C0422837	CNS relapses
T61	Disorder 572 589	systemic relapses
N15 	Reference T61 UMLS:C0277556	systemic relapses
T18	Subject 812 820	children
T8	Disorder 1447 1455	relapses
N16 	Reference T8 UMLS:C0277556	relapses
T21	Disorder 1588 1599	CNS relapse
N17 	Reference T21 UMLS:C0422837	CNS relapse
T24	Subject 117 125	children
T2	Subject 812 820	children
T6	Subject 593 601	children
T11	Combination 503 508	added
T26	Combination 1098 1108	additional
T28	Subject 1252 1264	653 patients
T30	Subject 1346 1349	323
T34	Subject 1393 1396	330
T23	Disorder 2003 2014	CNS relapse
N18 	Reference T23 UMLS:C0422837	CNS relapse
T35	Subject 2095 2103	children
T38	Subject 2095 2103	children
T39	Disorder 2417 2428	CNS relapse
N19 	Reference T39 UMLS:C0422837	CNS relapse
T40	Disorder 1932 1934	LL
N20 	Reference T40 UMLS:C0079748	LL
T41	Subject 1252 1264	653 patients
T43	Combination 2058 2061	and
T46	Speculation_cue 112 116	risk
T47	Subject 1275 1287	593 patients
T48	Subject 1316 1327	60 patients
T54	Negation_cue 2373 2379	failed
T55	Combination 2331 2336	added
